Dynamics of Ex Vivo Mesenchymal Stromal Cell Potency under Continuous Perfusion.

MSC bioreactor ex vivo therapy immunomodulation immunotherapy licensing secretome

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
31 May 2023
Historique:
received: 29 04 2023
revised: 21 05 2023
accepted: 23 05 2023
medline: 12 6 2023
pubmed: 10 6 2023
entrez: 10 6 2023
Statut: epublish

Résumé

Mesenchymal stromal cells (MSCs) are a candidate for cell immunotherapy due to potent immunomodulatory activity found in their secretome. Though studies on their secreted substances have been reported, the time dynamics of MSC potency remain unclear. Herein, we report on the dynamics of MSC secretome potency in an ex vivo hollow fiber bioreactor using a continuous perfusion cell culture system that fractionated MSC-secreted factors over time. Time-resolved fractions of MSC-conditioned media were evaluated for potency by incubation with activated immune cells. Three studies were designed to characterize MSC potency under: (1) basal conditions, (2) in situ activation, and (3) pre-licensing. Results indicate that the MSC secretome is most potent in suppressing lymphocyte proliferation during the first 24 h and is further stabilized when MSCs are prelicensed with a cocktail of pro-inflammatory cytokines, IFNγ, TNFα, and IL-1β. The evaluation of temporal cell potency using this integrated bioreactor system can be useful in informing strategies to maximize MSC potency, minimize side effects, and allow greater control for the duration of ex vivo administration approaches.

Identifiants

pubmed: 37298556
pii: ijms24119602
doi: 10.3390/ijms24119602
pmc: PMC10253999
pii:
doi:

Substances chimiques

Cytokines 0
Culture Media, Conditioned 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIBIB NIH HHS
ID : R01 EB012521
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB028782
Pays : United States
Organisme : NIH HHS
ID : R01EB012521
Pays : United States

Références

Cell Stem Cell. 2008 Feb 7;2(2):141-50
pubmed: 18371435
J Orthop Res. 2017 Jun;35(6):1151-1159
pubmed: 28294393
Stem Cells Transl Med. 2016 Aug;5(8):1004-13
pubmed: 27334487
Exp Mol Med. 2013 Nov 15;45:e54
pubmed: 24232253
J Vis Exp. 2022 Jul 20;(185):
pubmed: 35938803
Cell Stem Cell. 2013 Oct 3;13(4):392-402
pubmed: 24094322
Stem Cells Int. 2012;2012:652034
pubmed: 22685475
Cell Mol Immunol. 2012 Nov;9(6):473-81
pubmed: 23085948
Stem Cells Dev. 2015 Oct 1;24(19):2269-79
pubmed: 26192403
Cell Stem Cell. 2018 Jun 01;22(6):824-833
pubmed: 29859173
Front Immunol. 2012 Sep 26;3:297
pubmed: 23056000
J Tissue Eng Regen Med. 2012 May;6(5):369-77
pubmed: 21710576
PLoS One. 2007 Sep 26;2(9):e941
pubmed: 17895982
Stem Cells Transl Med. 2021 Dec;10(12):1588-1601
pubmed: 34581517
Mol Ther. 2018 Mar 7;26(3):860-873
pubmed: 29352647
Biol Blood Marrow Transplant. 2005 May;11(5):389-98
pubmed: 15846293
Exp Cell Res. 2018 Jan 1;362(1):102-110
pubmed: 29137914
Anal Biochem. 2021 Jul 15;625:114213
pubmed: 33887234
Sci Rep. 2020 Jun 23;10(1):10142
pubmed: 32576889
J Trauma Acute Care Surg. 2020 Aug;89(2S Suppl 2):S109-S117
pubmed: 32744836
Cells. 2021 Jul 08;10(7):
pubmed: 34359898
Cells. 2019 Sep 27;8(10):
pubmed: 31569696
Stem Cell Investig. 2022 Nov 08;9:7
pubmed: 36393919
Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):158-61
pubmed: 13129802
J R Soc Interface. 2020 Jun;17(167):20190815
pubmed: 32546114
Dent J (Basel). 2021 Sep 04;9(9):
pubmed: 34562975
Methods Mol Biol. 2013;979:65-70
pubmed: 23397389
Cell Mol Life Sci. 2020 Jul;77(14):2771-2794
pubmed: 31965214
Stem Cells Dev. 2016 Nov 15;25(22):1721-1732
pubmed: 27539289
Leukemia. 2011 Sep;25(9):1408-14
pubmed: 21617697
J Extracell Vesicles. 2014 Sep 30;3:
pubmed: 25317276
Annu Rev Biomed Eng. 2010 Aug 15;12:87-117
pubmed: 20415588
Front Immunol. 2019 Jul 31;10:1645
pubmed: 31417542
Cells. 2019 Mar 19;8(3):
pubmed: 30893822
Cytotherapy. 2014 Feb;16(2):191-202
pubmed: 24438900
Tissue Eng Part A. 2012 Jul;18(13-14):1479-89
pubmed: 22443121

Auteurs

Aneesha Doshi (A)

Department of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA.

Patrick Erickson (P)

Department of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA.

Matthew Teryek (M)

Department of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA.

Biju Parekkadan (B)

Department of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, USA.

Articles similaires

Killer Cells, Natural Animals Colorectal Neoplasms Decorin Adenoviridae

A dual role for PSIP1/LEDGF in T cell acute lymphoblastic leukemia.

Lisa Demoen, Filip Matthijssens, Lindy Reunes et al.
1.00
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Animals Mice Humans Cell Line, Tumor
Animals Natural Killer T-Cells Mice Adipose Tissue Lipid Metabolism
Animals Lung India Sheep Transcriptome

Classifications MeSH